Skip to content

Investigating the effect of coenzyme Q10 on the Progression of renal disease

The effect of coenzyme Q10 on the progression of chronic renal disease

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130812014333N124
Enrollment
90
Registered
2019-06-07
Start date
2019-06-05
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease. Chronic kidney disease, unspecified

Interventions

Intervention 1: The intervention group will receive a daily dose of 100 mg of Coenzyme Q10 tablet (Asia -KarAvaran Manufacturers) for 6 months. Intervention 2: The control group will receive 100 mg of

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of chronic kidney disease Glomerular filtration (GFR) below 60 and above 15 ml / min No history of hospitalization due to kidney disease ovation due to kidney disease over the past three months No increase in creatinine more than 50% over the past three months

Exclusion criteria

Exclusion criteria: Aged less than 18 years old; having allergies Pregnant women

Design outcomes

Primary

MeasureTime frame
Glomerular filtration rate (GFR). Timepoint: At the beginning of the intervention, 3 months and 6 months after the end of the intervention. Method of measurement: Based on test results.;Uric acid. Timepoint: At the beginning of the intervention, 3 months and 6 months after the end of the intervention. Method of measurement: Based on test results.;Creatinine. Timepoint: At the beginning of the intervention, 3 months and 6 months after the end of the intervention. Method of measurement: Based on test results.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahriar Manoochehri

Kermanshah University of Medical Sciences

shah.man20181397@gmail.com+98 83 3723 4989

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026